RISK BENEFIT ASSESSMENT
\ɹˈɪsk bˈɛnɪfˌɪt ɐsˈɛsmənt], \ɹˈɪsk bˈɛnɪfˌɪt ɐsˈɛsmənt], \ɹ_ˈɪ_s_k b_ˈɛ_n_ɪ_f_ˌɪ_t ɐ_s_ˈɛ_s_m_ə_n_t]\
Sort: Oldest first
-
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.